The gut microbiome as a potential source of non-invasive biomarkers of chronic obstructive pulmonary disease

Frontiers in Microbiology

Microbiology

Zhouli Dai¹  Pixin Ran²  Yumin Zhou²  Naijian Li²  Zhishan Deng²  Jinding Pu³  Xinzhu Yi⁴  Zhang Wang⁴  Chiyong Chen⁵  Bing Li⁵ 

[1] College of Medicine, Lishui University, Lishui, Zhejiang, China;Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China;Department of Respiratory Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China;Institute of Ecological Science, School of Life Science, South China Normal University, Guangzhou, Guangdong, China;The GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, Guangdong, China;

关键词: COPD;    gut microbiome;    metagenomics;    biomarker;    diagnosis;   

DOI  :  10.3389/fmicb.2023.1173614

 received in 2023-02-24, accepted in 2023-07-12,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundThe link between gut microbial dysbiosis and the development of chronic obstructive pulmonary disease (COPD) is of considerable interest. However, little is known regarding the potential for the use of the fecal metagenome for the diagnosis of COPD.MethodsA total of 80 healthy controls, 31 patients with COPD severity stages I or II, and 49 patients with COPD severity stages III or IV fecal samples were subjected to metagenomic analysis. We characterized the gut microbiome, identified microbial taxonomic and functional markers, and constructed a COPD disease classifier using samples.ResultsThe fecal microbial diversity of patients with COPD stages I or II was higher than that of healthy controls, but lower in patients with COPD stages III or IV. Twenty-one, twenty-four, and eleven microbial species, including potential pathogens and pro-inflammatory bacteria, were significantly enriched or depleted in healthy controls, patients with COPD stages I or II, and patients with COPD stages III & IV. The KEGG orthology (KO) gene profiles derived demonstrated notable differences in gut microbial function among the three groups. Moreover, gut microbial taxonomic and functional markers could be used to differentiate patients with COPD from healthy controls, on the basis of areas under receiver operating characteristic curves (AUCs) of 0.8814 and 0.8479, respectively. Notably, the gut microbial taxonomic features differed between healthy individuals and patients in stages I-II COPD, which suggests the utility of fecal metagenomic biomarkers for the diagnosis of COPD (AUC = 0.9207).ConclusionGut microbiota-targeted biomarkers represent potential non-invasive tools for the diagnosis of COPD.

【 授权许可】

Unknown   
Copyright © 2023 Li, Yi, Chen, Dai, Deng, Pu, Zhou, Li, Wang and Ran.